Last updated on: 10/01/2022
1. Contact details
Name of organisation
1) Department/Research group
2) Organisation/affiliationThe PHARMO Institute for Drug Outcomes Research
Short Name in the inventoryPHARMO Institute
Administrative Contact
Title Ms
Last name van Engeland
First name Heleen
Address line 1Van Deventerlaan 30-40
Address line 2
Address line 3
CityUtrecht
Postcode3528 AE
CountryNetherlands
Phone number (incl. country code)31307440800
Alternative phone number31307440805
Fax number (incl. country code)
Scientific Contact
Title Professor
Last name Herings
First name Ron
Address line 1Van Deventerlaan 30-40
Address line 2
Address line 3
CityUtrecht
Postcode3528 AE
CountryNetherlands
Phone number (incl. country code)31307440800
Alternative phone number31307440803
Fax number (incl. country code)
2. Description
The PHARMO Institute is an independent scientific research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources. The PHARMO Institute maintains a large and high quality Database Network and works closely with (inter)national medical universities and European healthcare database partners.
Through its studies with longitudinal and real-life patient data, the PHARMO Institute contributes to risk management, outcomes research and provides solutions for decision makers in market access, health economics and health outcomes domains.
3. Category
Independent Research Organisation
4. Available resources
In houseVia Contacts/Network
Epidemiologist/Pharmacoepidemiologist
Yes
Yes
Statistician
Yes
Yes
Clinician
No
Yes
Clinical Pharmacologist
No
Yes
Pharmacist
Yes
Yes
Geneticist/Pharmacogeneticist
No
Yes
IT specialist
Yes
Yes
Ethics expertise
No
Yes
Legal expertise
No
Yes
Regulatory expertise
Yes
Yes
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Congenital Malformations
Disorders of the central nervous system
Ear, nose and oropharynx disorders
Endocrine disorders
Eye disorders
Gastrointestinal tract
Geriatrics
Gynaecology
Immunological products and vaccines
Immunosuppression
Infectious diseases
Liver disease
Malignant disease
Musculoskeletal and joint diseases
Neonates
Nutrition and blood
Osteoporosis
Paediatrics
Pregnancy
Psychiatry
Renal impairment
Respiratory diseases
Skin disorders
Urinary tract disorders
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Meta-Analysis
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Less than 5
Number of patients/respondents involved in the study(ies)
Between 150 and 1499
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
Linked Patient Reported Outcomes System
Interactive voice response systems
No
Call centre
No
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
General Practitioner Database35
In- and Out-patient Pharmacy Database105
Clinical Laboratory Database20
Hospital Database75
Cancer and Pathology Registry10
11. Registries established by centre
Drug RegistryIn-patient and Out-patient pharmacy dispensing
Disease RegistryCancer registry, infectious disease registry
Other Perinatal registry, Pathology registry, Renine registry
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Other networks:
Network nameNationalInternationalLink to webpage
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Heintjes EM, Thomsen TL, Penning-van Beest FJ, Christensen TE, Herings RM. Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Adv Ther. 2010;27(4):211-22.http://www.pharmo.nl/common/page/allpublications
Heintjes EM, Penning-van Beest FJ, Plat AW, Meerding WJ, Webb K, Sturkenboom MC, et al. Cholesterol Level Goal Attainment with Statins: Clinical Management Guideline Recommendations versus Management in Actual Clinical Practice. Pharmacotherapy. 2012;32(7):631-41.http://www.pharmo.nl/common/page/allpublications
Overbeek JA, Penning-van Beest FJ, Balp MM, Dekhuijzen PN, Herings RM. Burden of Exacerbations in Patients with Moderate to Very Severe COPD in the Netherlands: A Real-life Study. COPD. 2015;12(2):132-43.http://www.pharmo.nl/common/page/allpublications
van Herk-Sukel MP, van de Poll-Franse LV, Creemers GJ, Lemmens VE, van der Linden PD, Herings RM, Coebergh JW, Voogd AC. Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands. The Breast Journal. 2013;19(4):394-401.http://www.pharmo.nl/common/page/allpublications
Kool-Houweling LM, Penning-van Beest FJ, Bezemer ID, van Lingen RA, Herings RM. Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands. Acta Paediatrica. 2015;104(9):927-32.http://www.pharmo.nl/common/page/allpublications
